Eloralintide produced 20% mean weight loss over 48 weeks at its top dose, against 0.4% on placebo — from a drug with no GLP-1 activity at all. The trial tested six regimens rather than a simple dose ladder, and reading them together shows something a single figure hides: how fast you climb changes what it costs you, without changing much of what you get.
All six arms
The phase 2 trial randomised 263 adults with obesity, or overweight plus a weight-related condition and without type 2 diabetes, across six eloralintide regimens or placebo for 48 weeks. Mean baseline weight was 109.1 kg and mean BMI 39.1; 78% were women.
| Arm | n | Mean weight change at 48 weeks | 95% CI |
|---|---|---|---|
| Placebo | 53 | −0.4% | −2.2 to 1.4 |
| 1 mg | 28 | −9% | −12.6 to −6.3 |
| 3 mg | 24 | −12% | −14.9 to −9.8 |
| 3 → 9 mg | 52 | −16% | −18.6 to −14.1 |
| 6 mg | 28 | −18% | −20.7 to −14.5 |
| 6 → 9 mg | 24 | −20% | −22.7 to −17.0 |
| 9 mg | 54 | −20% | −22.7 to −17.5 |
A clean dose-response from 9% at 1 mg to 20% at 9 mg, with placebo essentially flat.
Where you finish sets the weight loss
Compare the two arms that ended at 9 mg. The one that went straight there reached 20%; the one climbing from 6 mg also reached 20%. The arm climbing from 3 mg reached 16%.
So the destination dominates, with one qualification: the slowest climb gave up about four percentage points. That is the price of spending more of a 48-week trial at sub-maximal doses, and in a longer course it would probably shrink.
The other reading is that 6 mg is most of the way there. Eighteen per cent against twenty is a small gap for a third less drug, which matters if the higher dose is harder to tolerate — and it turns out it is not, which is where this gets interesting.
Where you start sets the nausea
The safety table does not follow the dose ladder at all.
| Arm | Weight loss | Nausea |
|---|---|---|
| Placebo | −0.4% | 14% |
| 1 mg | −9% | 11% |
| 3 mg | −12% | 13% |
| 3 → 9 mg | −16% | 25% |
| 6 mg | −18% | 64% |
| 6 → 9 mg | −20% | 54% |
| 9 mg | −20% | 33% |
The 6 mg arm produced less weight loss than the 9 mg arm and nearly twice the nausea. A lower dose cannot be harsher than a higher one if dose is what drives the reaction — so dose is not what drives it here.
What separates these arms is where they began. The two lowest-nausea arms started at 1 mg and 3 mg. The two highest started at 6 mg. The 9 mg fixed arm sits in between, which complicates the story rather than settling it, and the trial was not designed to isolate this.
Treated as a hypothesis rather than a finding, it says: a slower start buys most of the result at a fraction of the discomfort. The 3→9 mg arm reached 16% with 25% nausea; the 6 mg arm reached 18% with 64%. Four fifths of the effect for a third of the nausea is a trade most people would take.
Fatigue behaves differently, and that difference matters: it tracks the final dose rather than the starting one, reaching 43% at 9 mg and 46% on the 6→9 mg arm. Whatever mechanism produces the fatigue is not the one producing the nausea. Full figures in eloralintide side effects.
How 20% compares
| Drug | Mean weight loss | Duration | Phase |
|---|---|---|---|
| Retatrutide 12 mg | 24.2% | 48 weeks | 2 |
| Tirzepatide 15 mg | 20.9% | 72 weeks | 3 |
| Eloralintide 9 mg | 20% | 48 weeks | 2 |
| Semaglutide 2.4 mg | 14.9% | 68 weeks | 3 |
| Orforglipron 17.2 mg | 11.1% | 72 weeks | 3 |
Eloralintide matches tirzepatide in twenty-four fewer weeks, from a phase 2 trial a fraction of the size, without touching the GLP-1 receptor.
The caveats are the usual ones and they are real: 263 people, phase 2, and results in this field routinely come down at scale. But the comparison is not really about ranking. Every drug above eloralintide in that table works through GLP-1. Eloralintide does not, which means it can be added to them rather than replacing them — and combination trials with tirzepatide are running.
What has not been measured
- Responder rates. The published report gives means, not the proportions reaching 5%, 10% or 20% weight loss. Those are what tell you how wide the spread is, and they are the figures we would most like.
- Phase 3 efficacy. The programme has reached phase 3 with sixteen registered studies; nothing has reported.
- Combination results. Eloralintide plus tirzepatide is in trials, unreported.
- What happens after stopping. No withdrawal data. Weight returns after every drug in this field.
And the constraint underneath all of it: eloralintide is not approved and cannot be prescribed. What the drug is and where the programme stands is in the eloralintide overview; the approved options are ranked in the best GLP-1 for weight loss.
The rest of the set
What is eloralintide is the short introduction, and the comparisons are vs Zepbound, vs Wegovy and vs Ozempic.
Scientific References
2 sources- 1
Billings LK, Hsia S, Bays H, et al.
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
The Lancet · 406(10520) · 2025PMID: 41207310
- 2
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 387(3) · 2022PMID: 35658024
NEJM
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
How much weight do you lose on eloralintide?
In the 48-week phase 2 trial, mean weight loss was 20% on 9 mg, 18% on 6 mg, 12% on 3 mg and 9% on 1 mg, against 0.4% on placebo. The arm escalating from 3 mg to 9 mg reached 16%. Those are means from 263 people; the published report does not give responder rates, so how wide the spread was is not known.
Is eloralintide as effective as Zepbound?
On published figures, close: 20% at 48 weeks against tirzepatide's 20.9% at 72 weeks. Eloralintide's comes from a 263-person phase 2 and tirzepatide's from a 2,539-person phase 3, so the comparison is indicative rather than settled and phase 2 results often soften at scale. What makes it notable is that eloralintide achieves it without any GLP-1 activity.
Which eloralintide dose is best?
The trial suggests the answer depends on how you get there. Both 9 mg and the arm escalating from 6 mg to 9 mg reached 20%, while fixed 6 mg reached 18% — but fixed 6 mg also produced 64% nausea against 33% at 9 mg. The arm climbing from 3 mg reached 16% with only 25% nausea. Where you finish sets the weight loss; where you start appears to set the tolerability.
Why did the 6 mg dose cause more nausea than 9 mg?
Almost certainly because of how each arm started rather than where it ended. The fixed 6 mg arm began at 6 mg; the arms with the least nausea began at 1 or 3 mg. A lower dose cannot be inherently harsher than a higher one, so the difference has to come from the escalation. The trial was not designed to isolate this, so treat it as a strong hypothesis rather than a proven finding.
How does eloralintide work if it is not a GLP-1?
It activates the amylin receptor. Amylin is a hormone released by the pancreas alongside insulin after eating; it slows gastric emptying and signals satiety through its own receptors in the brainstem. The effect resembles what a GLP-1 drug achieves, by a separate route — which is why eloralintide can be combined with a GLP-1 rather than competing with it.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.